Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk - Summary - MDSpire

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk

  • By

  • Jun Luo

  • Yinzhong Dai

  • Chenguang Wu

  • Chengying Lan

  • Junwei Shi

  • Jinfeng Qi

  • Shimei Hua

  • Yan An

  • Lifan Wang

  • Ping Li

  • Peng Liu

  • May 29, 2026

Share

Objective:

Keep as is.

Key Findings:
  • Include confidence intervals for each finding.
Interpretation:

Remove this section.

Limitations:
  • Add specificity regarding variability in renal effects.
Conclusion:

Revise to reflect only findings without unsupported claims.

Original Source(s)

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk

  • by Jun Luo, Yinzhong Dai, Chenguang Wu, Chengying Lan, Junwei Shi, Jinfeng Qi, Shimei Hua, Yan An, Lifan Wang, Ping Li, Peng Liu

  • May 29, 2026

Related Content